Stocks•6 October 2026•
1 min read
Scotiabank Raises AbbVie Price Target to $320
Key Facts
1Scotiabank increased its price target for AbbVie to $320 from $280 while maintaining a Sector Outperform rating.
2The new price target implies a 20.4% upside from the stock's closing price on October 5th.
3The positive outlook is driven by a robust immunology and oncology portfolio and growth from recent acquisitions including Allergan, Cerevel, and ImmunoGen.
Scotiabank increased its price target for AbbVie to $320 from $280 while maintaining a Sector Outperform rating. According to TradingView, the new target implies a potential upside of 20.4% relative to the stock's closing price on October 5th.
The positive outlook is driven by AbbVie's robust immunology and oncology portfolios and growth following the acquisitions of Allergan, Cerevel, and ImmunoGen. ABBV closed at $265.76 on October 5, 2026, after trading between a session low of $260.29 and a high of $267.34.